Medline Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Medline Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.43B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $25.51B | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $23.23B | Feb 25, 2026 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.52B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $6.98B | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $5.89B | Feb 25, 2026 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.00M) | Feb 25, 2026 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.21B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $2.15B | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $1.25B | Feb 25, 2026 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $80.00M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $67.00M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $60.00M | Feb 25, 2026 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.52B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $4.11B | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $3.87B | Feb 25, 2026 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.74B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.77B | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $1.69B | Feb 25, 2026 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $447.00M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $354.00M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $275.00M | Feb 25, 2026 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $38.48B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $35.98B | Feb 25, 2026 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.20B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $19.45B | Feb 25, 2026 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.74B | Feb 25, 2026 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.08B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $8.07B | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $7.53B | Feb 25, 2026 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.00M) | Feb 25, 2026 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.94B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $199.00M | Feb 25, 2026 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 25, 2026 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 25, 2026 |